Overview
A long-duration regenerative framework designed to address chronic musculoskeletal pain and degenerative soft tissue conditions. This protocol emphasizes sustained anti-inflammatory modulation, connective tissue remodeling, and sleep-optimized recovery over an extended treatment window. Unlike acute protocols, this approach prioritizes compliance, gradual tissue repair, and long-term functional stabilization.
Clinical Scope
| Chronic low back pain |
| Fibromyalgia |
| Myofascial pain syndrome |
| Chronic tendinopathy |
| Degenerative musculoskeletal conditions |
Expected Outcomes
| Gradual reduction in persistent pain |
| Improved soft tissue resilience |
| Enhanced functional capacity |
| Reduction in inflammatory flare frequency |
| Improved sleep-driven recovery |
Core Chronic Pain Stack
BPC-157
| Administration Route: SubQ + Oral |
| Dose: 250 mcg SubQ + 250 mcg Oral |
| Frequency: Twice daily |
| Duration: 12–16 weeks |
TB-500 (Thymosin β4)
| Administration Route: SubQ |
| Dose: 1.0–1.5 mg |
| Frequency: Once weekly |
| Duration: 12 weeks |
KPV
| Administration Route: Oral |
| Dose: 500 mcg |
| Frequency: Daily |
| Duration: 8–12 weeks |
CJC-1295 / Ipamorelin
| Administration Route: SubQ |
| Dose: 100 mcg / 100 mcg |
| Frequency: Once daily (evening) |
| Duration: 16 weeks |
DSIP
| Administration Route: SubQ |
| Dose: 100–200 mcg |
| Frequency: Nightly (before bed) |
| Duration: 4–8 weeks (front-loaded) |
Phase Structure
Phase 1: Stabilization (Weeks 1–4)
| Initiate BPC-157 oral + SubQ split dosing |
| Begin TB-500 weekly |
| Start KPV oral anti-inflammatory support |
| Initiate CJC-1295 / Ipamorelin nightly |
| Use DSIP nightly to improve sleep architecture |
Phase 2: Sustained Remodeling (Weeks 5–12)
| Maintain BPC-157 dual-route dosing |
| Continue TB-500 weekly |
| Continue GH secretagogues nightly |
| Taper DSIP once sleep stabilizes |
| Reassess pain trend and functional capacity |
Phase 3: Long-Term Consolidation (Weeks 13–16)
| Continue CJC-1295 / Ipamorelin |
| Taper BPC-157 to maintenance dosing if improved |
| Discontinue TB-500 at Week 12 |
| Discontinue KPV after 8–12 weeks |
Rationale
Chronic musculoskeletal pain requires a slower, sustained approach compared to acute protocols. The oral and SubQ split of BPC-157 provides systemic anti-inflammatory modulation through the gut-brain axis while supporting localized tissue repair. TB-500 enhances cellular migration and long-term structural remodeling. KPV offers controlled inflammatory regulation without systemic suppression. CJC-1295/Ipamorelin are maintained throughout the full duration to support continuous tissue remodeling via growth hormone and IGF-1 signaling. DSIP is front-loaded to disrupt the pain–poor sleep cycle and optimize recovery during the early phase of treatment.
Monitoring
| VAS pain scoring |
| Functional movement assessment |
| Sleep quality tracking |
| Inflammatory markers when clinically indicated |
| IGF-1 monitoring during GH secretagogue use |
Contraindications
| Active malignancy |
| Pregnancy or breastfeeding |
| Uncontrolled endocrine disorders |
| Active systemic infection |
| Known hypersensitivity to any compound |
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Clinical Disclaimer
This protocol is provided for informational and educational purposes for licensed healthcare professionals. These compounds and strategies are not intended to diagnose, treat, cure, or prevent any disease. Patient-specific evaluation and clinical judgment are required prior to implementation.